Assorted News from the Last Week:

The impact of focused federal initiatives on pediatric cancer research: continuous support for both CCDI and the STAR Act has been critical for accelerating progress in childhood cancer.

CAC2 Supporting Organization Member Day One Biopharmaceuticals, Inc. announced it has signed a definitive merger agreement to acquire Mersana Therapeutics.  The company hopes to continue development of Emi-Le an ADC directed against B7-H4, a well-characterized target highly expressed in ACC as well as in other adult and pediatric cancers.

CAC2 Member The Medulloblastoma Initiative and Hospital Israelita Albert Einstein signed a memorandum of understanding to accelerate research and treatment of pediatric brain tumors. 

Computational deep dive reveals hidden cancer drug targets and repurposing opportunities.

Newly identified T-cell subtype may explain treatment-resistant childhood leukemia.

Food insecurity linked to tumor growth in pediatric neuroblastoma.

Genetic technique may enable precision treatment of pediatric brain tumors.

Upcoming Webinars, Online Opportunities, and Meetings:

Christmas at Children’s National Toy Drive sponsored by Liv’s Creative Legacy, November 7 through December 4.  Click here for more information.

Register now for an NCI webinar on Liquid Biopsy for Retinoblastoma on December 9, at 1:00 ET.

The Science of Childhood Cancer is an interactive, weekly lecture series designed to engage the scientific community on key questions in pediatric cancer research. The Fall 2025 lecture season will run August 14 through November 20. Click here for more information and to register.

Action Days 2026 will be held in Washington, D.C. from February 24-25, 2026. Registration is open! Action Days registration will close on Friday, January 30, or when we reach 225 participants. Click here for more information and to register.